Study of a new IVIG for primary immune deficiency
Part of Genetic & congenital, Immune system & allergy clinical trials.
This trial tests an investigational intravenous immunoglobulin (IVIG) called Boya for people with primary immune deficiencies like CVID or XLA. It aims to see if the treatment is safe and works well to prevent infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 2 to 60 years old
- Diagnosed with common variable immune deficiency (CVID) or X-linked agammaglobulinemia (XLA)
- Currently not on IVIG or getting it every 21–28 days at a dose between 300 and 800 mg per kg of body weight
- If you can become pregnant, must have a negative pregnancy test and use effective birth control during the study
- No known allergy to immunoglobulins or any part of the study drug
- No active infection or fever in the past two weeks before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new intravenous immunoglobulin (IVIG) treatment for patients with primary immunodeficiency diseases, such as common variable immune deficiency (CVID) or X-linked agammaglobulinemia (XLA). It aims to see if this medicine is safe and works well to prevent infections.
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
This study examines how well immunoglobulin replacement therapy works in people with primary antibody immunodeficiency—a rare condition where the body cannot make enough antibodies to fight infections. Researchers will also study immune system changes to understand treatment response better.
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
Hear when a new Primary Immunodeficiency Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.